Drug Resistance Mutations
Drug Resistance Mutations - Related Videos
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
0 Views •
Cited by 2 •
2015
Drug resistance to targeted therapeutics is widespread and the need to identify mechanisms of resistance--prior to or following clinical onset--is critical for guiding alternative clinical management strategies. Here, we present a protocol to couple derivation of drug-resistant lines in vitro with sequencing to expedite discovery of these mechanisms.
04:17
Dose Escalation: A Method for Developing Drug Resistance in Cancer Cells
0 Views •
2023
The video describes the development of drug resistance in cancer cells by exposing cells to escalating doses of a drug after calculating IC50 values of the drug previously with MTT assay. The sample protocol describes the step-by-step process of developing drug-resistant cells.
07:35
Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray
0 Views •
Cited by 4 •
2014
An amplification microarray combines asymmetric PCR amplification and microarray hybridization into a single chamber, which significantly streamlines microarray workflow for the end user. Simplifying microarray workflow is a necessary first step for creating microarray-based diagnostics that can be routinely used in lower-resource environments.
00:36
Viral Mutations
0 Views •
2019
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
11:37
QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii
0 Views •
Cited by 5 •
2017
Details are presented on how QTL mapping with a whole genome sequence based genetic map can be used to identify a drug resistance gene in Toxoplasma gondii and how this can be verified with the CRISPR/Cas9 system that efficiently edits a genomic target, in this case the drug resistance gene.
FAQs
Their effects can arise at several points in drug action. A mutation may alter the molecular target so the drug binds less effectively, reduce drug entry, increase efflux that removes the compound, or change drug activation and metabolism. These mechanisms can operate in microorganisms or cancer cells, producing different routes to reduced sensitivity in medicine.
Treatment pressure changes which cells remain in a population: cells carrying advantageous resistance variants are more likely to survive while sensitive cells are reduced. The surviving population can therefore become dominated by variants that tolerate the drug. This selection process explains why resistance may become clinically important during therapy and contribute to treatment failure.
Genomic or molecular testing can identify resistance mutations and help distinguish reduced sensitivity that was present initially from resistance acquired during treatment. This distinction matters because acquired resistance suggests that therapy favored a later advantageous variant, whereas baseline insensitivity indicates that the original drug may have been unsuitable from the outset.
Genomic or molecular testing identifies resistance mutations that can influence therapeutic decisions. Clinicians can use the findings to guide drug selection and support personalized treatment. In practice, the result connects a genetic change with a treatment choice, helping medicine respond to resistance through targeted management rather than relying only on a uniform approach.
Monitoring resistance mutations can reveal whether treatment pressure is favoring resistant variants and can help explain disease progression or therapeutic failure. In antimicrobial care, this information supports stewardship by informing drug choices. In oncology, tracking resistance can help clinicians reassess therapy as cancer cells become less responsive to the selected treatment.
Combination therapies are relevant because treatment strategies using more than one drug are designed to limit resistance. This approach complements mutation monitoring and informed drug selection by addressing the possibility that a population may contain variants with different survival advantages. It connects knowledge of resistance mechanisms with broader planning for antimicrobial and cancer treatment.